Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Recommendation of "Buy" from Analysts

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) have earned a consensus recommendation of "Buy" from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have covered the stock in the last year is $78.00.

Several research analysts have issued reports on the company. Citigroup assumed coverage on Structure Therapeutics in a report on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective on the stock. William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. Finally, HC Wainwright reduced their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Monday.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Aberdeen Group plc lifted its stake in shares of Structure Therapeutics by 45.2% in the 1st quarter. Aberdeen Group plc now owns 248,899 shares of the company's stock valued at $4,308,000 after purchasing an additional 77,511 shares during the period. Invesco Ltd. lifted its stake in shares of Structure Therapeutics by 6.1% in the 1st quarter. Invesco Ltd. now owns 394,386 shares of the company's stock valued at $6,827,000 after purchasing an additional 22,619 shares during the period. National Bank of Canada FI increased its position in shares of Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after buying an additional 2,766 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its position in shares of Structure Therapeutics by 310.7% in the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock valued at $74,000 after buying an additional 3,213 shares in the last quarter. Finally, Readystate Asset Management LP increased its position in shares of Structure Therapeutics by 129.9% in the 1st quarter. Readystate Asset Management LP now owns 481,241 shares of the company's stock valued at $8,330,000 after buying an additional 271,899 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Price Performance

NASDAQ GPCR opened at $23.89 on Wednesday. The firm has a market cap of $1.37 billion, a PE ratio of -32.28 and a beta of -1.69. Structure Therapeutics has a one year low of $13.22 and a one year high of $62.74. The stock's 50 day simple moving average is $20.98 and its 200 day simple moving average is $26.75.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, equities analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.